Palvella Therapeutics Inc (NASDAQ:PVLA) shares gained 5% in premarket trading on Monday after the company announced that the U.S. Food and Drug Administration had granted rolling review status to its New Drug Application (NDA) for QTORIN rapamycin, a treatment for microcystic lymphatic malformations.
The regulatory development marks another step forward in the company’s efforts to bring the therapy to market and could potentially accelerate the review process.
Rolling Review Expected to Streamline NDA Evaluation
Under the FDA’s rolling review framework, Palvella can submit completed sections of its NDA as they are finalized rather than waiting for the entire application package to be completed.
This approach allows regulators to begin reviewing portions of the submission earlier, potentially shortening the overall assessment timeline.
The company said it remains on schedule to complete the full NDA submission during the second half of 2026.
Potential First Approved Treatment for a Rare Condition
If approved, QTORIN rapamycin would become the first FDA-authorized therapy specifically indicated for microcystic lymphatic malformations.
The rare genetic disorder is estimated to affect more than 30,000 people across the United States.
Patients with the condition develop abnormal lymphatic vessels that can extend through the skin, leading to chronic leakage, bleeding, recurring infections and, in some cases, repeated hospitalizations.
Multiple FDA Designations Support Development
QTORIN rapamycin has already received several regulatory designations intended to support and accelerate its development.
The therapy has been awarded Breakthrough Therapy Designation, Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of microcystic lymphatic malformations.
Rolling review eligibility is reserved for therapies that have received Fast Track or Breakthrough Therapy status and are targeting serious diseases with significant unmet medical needs.
Targeted Delivery Approach Aims to Improve Treatment Outcomes
QTORIN rapamycin has been developed to deliver rapamycin directly to affected skin tissue, targeting the abnormal mTOR signaling pathway that drives disease progression.
The localized delivery strategy is designed to maximize therapeutic activity at the site of disease while reducing systemic exposure to the drug.
Currently, there are no FDA-approved treatment options available for patients with microcystic lymphatic malformations in the United States, highlighting the potential significance of the therapy if it successfully completes the regulatory review process.